Article
Oncology
Yingmei Li, Dina Polyak, Layton Lamsam, Ian David Connolly, Eli Johnson, Lina Khav Khoeur, Stephanie Andersen, Monica Granucci, Geoff Stanley, Boxiang Liu, Seema Nagpal, Melanie Hayden Gephart
Summary: This study utilized single-cell RNA-seq and cell-free RNA analysis to diagnose NSCLC leptomeningeal metastases and found that tumor-associated genes were present in the cerebrospinal fluid. The gene CEACAM6 was identified to play a significant role in NSCLC migration in the brain, which is a hallmark of leptomeningeal metastases.
NPJ PRECISION ONCOLOGY
(2021)
Article
Oncology
Inna Smalley, Zhihua Chen, Manali Phadke, Jiannong Li, Xiaoqing Yu, Clayton Wyatt, Brittany Evernden, Jane L. Messina, Amod Sarnaik, Vernon K. Sondak, Chaomei Zhang, Vincent Law, Nam Tran, Arnold Etame, Robert J. B. Macaulay, Zeynep Eroglu, Peter A. Forsyth, Paulo C. Rodriguez, Y. Ann Chen, Keiran S. M. Smalley
Summary: This study used single-cell RNA sequencing to define the immune landscape of melanoma CNS metastases in different sites. The results showed that immune environment in LMM was distinct from MBM and skin metastases, and therapy in MBM patients led to increased immune infiltrate.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Naoki Niikura, Takashi Yamanaka, Hironori Nomura, Kazuhiro Shiraishi, Hiroki Kusama, Mitsugu Yamamoto, Kazuo Matsuura, Kenichi Inoue, Sachiko Takahara, Shosuke Kita, Miki Yamaguchi, Tomoyuki Aruga, Nobuhiro Shibata, Akihiko Shimomura, Yuri Ozaki, Shuji Sakai, Yoko Kiga, Tadahiro Izutani, Kazuhito Shiosakai, Junji Tsurutani
Summary: This study reports on the effectiveness and safety of trastuzumab deruxtecan in breast cancer patients with brain metastases and leptomeningeal carcinomatosis. The results show that trastuzumab deruxtecan provides disease control in both the brain and systemic levels, with a satisfactory overall response rate and progression-free survival.
Article
Biotechnology & Applied Microbiology
Darshini Kuruppu, Deepak Bhere, Christian T. Farrar, Khalid Shah, Anna-Liisa Brownell, Umar Mahmood Umar Mahmood, Kenneth K. Tanabe
Summary: This study investigates the therapeutic efficacy of oncolytic Herpes simplex virus 1 (HSV1) on different stages of breast cancer leptomeningeal metastases growth. The results show that targeting the lag and intermediate phases of the disease can inhibit tumor growth, delay symptoms onset, and extend survival.
CANCER GENE THERAPY
(2023)
Article
Oncology
Milan Zhang, Jiayi Tong, Weifeng Ma, Chongliang Luo, Huiqin Liu, Yushu Jiang, Lingzhi Qin, Xiaojuan Wang, Lipin Yuan, Jiewen Zhang, Fuhua Peng, Yong Chen, Wei Li, Ying Jiang
Summary: This study investigates prognostic indicators for lung adenocarcinoma with leptomeningeal metastases (LM) and develops an updated graded prognostic assessment model integrated with molecular alterations (molGPA). By analyzing data from 162 patients, the study identifies four predictors and successfully develops a new prognostic model with improved predictive performance.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Qing Li, Zhen Lin, Ye Hong, Yang Fu, Yueyun Chen, Ting Liu, Yue Zheng, Jiangfang Tian, Chunhua Liu, Wei Pu, Zhenyu Ding, Chun Wang
Summary: Patients with advanced non-small cell lung cancer are susceptible to brain metastases, including brain parenchymal metastases and leptomeningeal metastases. Patients with leptomeningeal metastases have a higher proportion of EGFR exon 21 point mutations and shorter survival compared to patients without brain metastases or with brain parenchymal metastases. Two prediction models were developed to predict the development of brain parenchymal metastases and leptomeningeal metastases in advanced non-small cell lung cancer patients.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, Research & Experimental
Xin Chen, Kaixuan Bai, Yu Zhang, Yang Xu, Yinghao Huo, Sha Wang, Yueli Zou, Xuejiao Qi, Rongyun Guo, Qiuxiang Ou, Dengxiang Liu, Shaohua Yin, Shubo Chen, Hui Bu
Summary: In this study, it was found that cerebrospinal fluid circulating tumor DNA could sensitively detect molecular markers and metastasis-related mechanisms in gastric cancer patients with leptomeningeal metastases, providing new clues for prognosis estimation and clinical assessment.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Review
Oncology
Yan Wang, Xue Yang, Nan-Jing Li, Jian-Xin Xue
Summary: Leptomeningeal metastasis (LM) is a rare and highly fatal complication of non-small cell lung cancer (NSCLC). Improving the diagnosis and treatment of LM is crucial, as it severely affects patients' quality of life. Understanding the potential mechanisms of LM is helpful in addressing this issue. Clinical manifestations, magnetic resonance imaging, and CSF biopsy are key components in the diagnosis, and CSF cytology should be combined with liquid biology. Treatment options for LM patients include radiotherapy, intrathecal treatment, targeted therapy, and immunotherapy.
Article
Oncology
Nayan Lamba, Patrick Y. Wen, Ayal A. Aizer
Summary: Brain metastases significantly impact patients with advanced extracranial malignancies, but their incidence remains poorly described. Recent studies have shown the viability of using claims data for epidemiologic investigations of brain metastases.
Review
Oncology
Stefania Morganti, Heather A. Parsons, Nancy U. Lin, Albert Grinshpun
Summary: A subset of metastatic breast cancer patients develop brain metastasis, and as systemic therapies have improved, the incidence of breast cancer brain metastases has increased. Brain metastases pose challenges in diagnosis, treatment, and monitoring in all subtypes of breast cancer, and liquid biopsy offers a potential solution. This review focuses on the clinical validity of liquid biopsy, specifically circulating tumor cells and circulating tumor DNA, in patients with breast cancer brain metastases.
Review
Oncology
Ajay Dhakal, Amanda E. D. Van Swearingen, Ruth O'Regan, Carey K. Anders
Summary: Brain metastasis from breast cancer has a poor prognosis. Systemic chemotherapy and targeted therapies often do not work against brain metastasis. Local therapies are typically used upfront, followed by systemic therapies.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Review
Clinical Neurology
Jessica A. Wilcox, Min Jun Li, Adrienne A. Boire
Summary: Leptomeningeal metastases, which can cause significant neurological damage and death, remains a challenging disease to treat. However, there is hope as several studies and clinical trials have shown that certain cancer-directed strategies are effective in improving survival rates for patients with this condition. Further clinical trials are needed to establish the efficacy of treatments and to explore new avenues of treatment.
Review
Oncology
Matthew N. Mills, Whitney King, Aixa Soyano, Yolanda Pina, Brian J. Czerniecki, Peter A. Forsyth, Hatem Soliman, Hyo S. Han, Kamran A. Ahmed
Summary: Patients with HER2-positive breast cancer are at a high risk of breast cancer brain metastasis and leptomeningeal disease. The management of these cases is rapidly evolving and requires a multidisciplinary approach. Advances in systemic therapy have improved survival, and ongoing clinical trials are investigating potential targeted therapies.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Oncology
Qiuyue Ye, Yan Xu, Jing Zhao, Xiaoxing Gao, Minjiang Chen, Ruili Pan, Wei Zhong, Mengzhao Wang
Summary: This study investigated the factors affecting the prognosis of EGFR-mutant NSCLC patients with leptomeningeal metastases (LM) and compared the survival benefit of osimertinib-treated patients with those untreated. The results showed that osimertinib can prolong the overall survival of patients with LM and improve patient outcomes.
TRANSLATIONAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Jhih-Kai Pan, Wen-Der Lin, Yao-Lung Kuo, Yu-Chia Chen, Zhu-Jun Loh, Forn-Chia Lin, Hui-Chuan Cheng, Michael Hsiao, Pei-Jung Lu
Summary: Through proteomic analysis, high expression of ICAM2 was found in leptomeningeal metastatic TNBC cells, promoting spinal cord colonization and causing poor survival outcomes. Two-way demonstration showed that high levels of ICAM2 promoted BCB adhesion, migration, and stemness abilities, determining the specificity of LM in vivo. The study suggests that targeting ICAM2 is a potential therapeutic strategy for LM in TNBC.
Article
Radiology, Nuclear Medicine & Medical Imaging
Seung Wan Kang, Won Gi Jeong, Jong Eun Lee, In-Jae Oh, Sang Yun Song, Byung Chan Lee, Yun-Hyeon Kim
Summary: This study aimed to determine the prognostic significance of central lung cancer in resected T1-sized early-stage non-small cell lung cancer (NSCLC). The results showed that central lung cancer, defined by a location index, was adversely associated with relapse-free survival and overall survival. It was found to be an independent adverse prognostic factor in early-stage NSCLC.
Article
Oncology
Yong-Hyub Kim, Sung-Ja Ahn, Sung Ho Moon, Jin Hee Kim, Young-Chul Kim, In-Jae Oh, Cheol Kyu Park, Jae-Uk Jeong, Mee Sun Yoon, Ju-Young Song, Chang-Ok Suh, Kwan Ho Cho, Sun Hyo Park
Summary: We conducted a clinical trial to compare the efficacy of accelerated hypofractionated radiation therapy (RT) with conventionally fractionated 60-Gy RT in patients with stage III unresectable non-small cell lung cancer (NSCLC). The results showed no significant differences in treatment response, overall survival, progression-free survival, and local tumor control rates between the two groups. This suggests that accelerated hypofractionated RT may not be superior to conventional fractionation in patients with unresectable stage III NSCLC undergoing concurrent chemoradiation therapy.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Pharmacology & Pharmacy
Jieun Kang, Man Pyo Chung, Moo Suk Park, In Jae Oh, Heung Bum Lee, Young Whan Kim, Jong Sun Park, Soo Taek Uh, Yun Seong Kim, Yangjin Jegal, Jin Woo Song
Summary: This study evaluated the impact of reduced dose of pirfenidone on clinical outcomes in patients with IPF. The results showed that reduced doses did not have a negative impact on clinical outcomes compared to standard-dose pirfenidone, suggesting that dose reduction may be a useful method to manage adverse events while maintaining therapeutic efficacy.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemical Research Methods
Seungwon Oh, Sae-Ryung Kang, In-Jae Oh, Min-Soo Kim
Summary: The study aimed to improve survival prediction in patients with non-small cell lung cancer (NSCLC) by incorporating prognostic information from F-18 fluorodeoxyglucose positron emission tomography (FDG PET) images into a traditional survival prediction model using clinical data. The multimodal deep learning model showed the best performance, with a C-index and mean absolute error of 0.756 and 399 days under a five-fold cross-validation, respectively, followed by ResNet3D for PET (0.749 and 405 days) and CPH for clinical data (0.747 and 583 days).
BMC BIOINFORMATICS
(2023)
Article
Oncology
Cheol-Kyu Park, Nakyung Jeon, Hwa-Kyung Park, Hyung-Joo Oh, Young-Chul Kim, Ha-Lim Jeon, Yong-Hyub Kim, Sung-Ja Ahn, In-Jae Oh
Summary: In this retrospective cohort study, durvalumab consolidation (DC) after concurrent chemoradiotherapy (CCRT) was found to be associated with survival benefits in real-world contexts, supporting its establishment as a new standard of care for stage III NSCLC. The study aimed to provide real-world evidence regarding the effectiveness and safety of DC after CCRT in the treatment of unresectable stage III NSCLC.
Article
Oncology
Cheol-Kyu Park, Sung-Woo Lee, Hyun-Ju Cho, Hyung-Joo Oh, Young-Chul Kim, Yong-Hyub Kim, Sung-Ja Ahn, Jae-Ho Cho, In-Jae Oh
Summary: A total of 50 patients with unresectable stage III NSCLC who received CCRT between March 2020 and March 2021 were recruited. Durvalumab consolidation (DC) was administered to patients (n=23) without progression after CCRT and programmed death-ligand 1 (PD-L1) ≥1%. Blood samples collected before (C0) and after CCRT (C1) were analyzed to calculate PBC counts and examine CTCs. The study found that the presence of residual CTC clusters at C1 and high platelet counts at C1 (PLThi) were independent risk factors for worse progression-free survival (PFS). The study suggests that the clearance of CTC clusters and platelet counts at C1 could serve as potential biomarkers for predicting survival.
Article
Cell Biology
Cheol-Kyu Park, Ha Ra Jun, Hyung-Joo Oh, Ji-Young Lee, Hyun-Ju Cho, Young-Chul Kim, Jeong Eun Lee, Seong Hoon Yoon, Chang Min Choi, Jae Cheol Lee, Sung Yong Lee, Shin Yup Lee, Sung-Min Chun, In-Jae Oh
Summary: This study aimed to investigate the feasibility of blood-based biomarkers, including blood tumor mutation burden (bTMB), to predict atezolizumab efficacy in relapsed and advanced non-small cell lung cancer (NSCLC). The results suggest that baseline levels and dynamic changes of blood-based biomarkers can predict atezolizumab efficacy in previously treated NSCLC patients.
Article
Oncology
Ha-Young Park, Joo-Heon Park, Myung-Geun Shin, Seung Jung Han, Yong-Sok Ji, Hyung-Joo Oh, Young-Chul Kim, Taebum Lee, Yoo-Duk Choi, In-Jae Oh
Summary: This case report presents a rare case of ultra-late recurrence of NSCLC with choroidal metastasis and KIF13A-RET fusion in a 48-year-old female never-smoker. The patient had undergone lobectomy followed by adjuvant chemotherapy 14 years prior. Choroidal metastatic lesions were observed, along with bone and uterine metastases. Liquid-based NGS confirmed the presence of KIF13A-RET fusion, and the patient showed a partial response to selpercatinib therapy.
FRONTIERS IN ONCOLOGY
(2023)
Letter
Oncology
Cheol-Kyu Park, In-Jae Oh, Young-Chul Kim
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Article
Oncology
In-Jae Oh, Cheol-Kyu Park, Kyoung-Bok Min, Jin-Young Min, Chaeuk Chung, Seong-Hoon Yoon, Changsoo Kim, Sei-Hoon Yang
Summary: A study in Korea found that lung cancer patients exposed to high concentrations of PM2.5 had significantly increased healthcare utilization and drug prescriptions.
Article
Medicine, General & Internal
Min-Gwan Sun, Sue Jee Park, Yeong Jin Kim, Kyung-Sub Moon, In-Young Kim, Shin Jung, Hyung-Joo Oh, In-Jae Oh, Tae-Young Jung
Summary: There is ongoing controversy regarding whether to use radiologic follow-up or local treatment for asymptomatic small-sized brain metastases from primary lung cancer. This study evaluated the potential factors related to brain progression and the effectiveness of systemic therapy in controlling tumors without local treatment. The results showed that targeted therapy was superior to cytotoxic chemotherapy in the treatment of these brain metastases, offering the opportunity to determine the optimal timing for local treatment while reducing the risk of brain-related mortality.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Hwa Kyung Park, Yoo Duk Choi, Ju-Sik Yun, Sang-Yun Song, Kook-Joo Na, Joon Young Yoon, Chang-Seok Yoon, Hyung-Joo Oh, Young-Chul Kim, In-Jae Oh
Summary: This study investigated the prevalence of genetic alterations in early-stage non-small cell lung cancer (NSCLC) and the association between EGFR mutations and recurrence after surgical resection. The presence of EGFR mutations was found to be an independent risk factor for recurrence and was associated with systemic recurrence. Targeted therapy should be considered more actively as an adjuvant or neoadjuvant treatment option.
Article
Oncology
Wonjun Ji, In-Jae Oh, Cheol-Kyu Park, Sung Yong Lee, Juwhan Choi, Jae Cheol Lee, Jiwon Kim, Seung Hyeun Lee
Summary: This study provides real-world evidence of the effectiveness and safety of afatinib as a treatment option for patients with squamous cell carcinoma of the lung (LSCC) who have progressed after chemotherapy and immunotherapy. The study also highlights the potential predictive value of the ERBB2 mutation as a biomarker in clinical settings.
Meeting Abstract
Oncology
C. -K. Park, H. R. Jun, H. -J. Oh, J. -Y. Lee, H. -J. Cho, Y. -C. Kim, J. E. Lee, S. H. Yoon, C. M. Choi, J. C. Lee, S. Y. Lee, S. Y. Lee, S. -M. Chun, I. -J. Oh
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Medicine, General & Internal
Jae-Kyeong Lee, Yu-Il Kim, Sun-Seog Kweon, In-Jae Oh, Yong-Soo Kwon, Hong-Joon Shin, Yu-Ri Choe, Ha-Young Park, Young-Ok Na, Hwa-Kyung Park
Summary: This study found that smoking cessation rates in the elderly are comparable to that in the nonelderly after an intensive care smoking cessation camp. Intensive care smoking cessation camps can help both elderly and nonelderly smokers who intend to quit smoking by providing motivation, education, and medication. Smoking cessation should be strongly recommended regardless of age.
Article
Clinical Neurology
Hyunjung Kim, Jhii-Hyun Ahn, Sung Min Ko, Jin Woo Kim
Summary: The pre-navigation balloon technique significantly reduces the occurrence of distal embolism and increases the first-pass effect (FPE) during stent retriever thrombectomy. This technique is particularly effective for patients with ICA occlusion, improving clinical outcomes.
CLINICAL NEUROLOGY AND NEUROSURGERY
(2024)
Review
Clinical Neurology
Mehdi Khaleghi, Joshua Vignolles-Jeong, Bradley Otto, Ricardo Carrau, Daniel Prevedello
Summary: This study presented a rare case of symptomatic ectopic Rathke's cleft cyst (RCC), which was located posterior to the pituitary gland and caused extensive clival erosion. The surgical technique of wide marsupialization of the cyst using intraoperative ultrasound-assisted endoscopic endonasal transclival approach was described, and a systematic literature review of intracranial ectopic RCCs was conducted.
CLINICAL NEUROLOGY AND NEUROSURGERY
(2024)
Article
Clinical Neurology
Oscar H. Del Brutto, Denisse A. Rumbea, Aldo F. Costa, Maitri Patel, Mark J. Sedler, Robertino M. Mera
Summary: This study found an association between cognitive impairment and mortality risk in adults of Amerindian ancestry living in rural Ecuador.
CLINICAL NEUROLOGY AND NEUROSURGERY
(2024)
Article
Clinical Neurology
Yangjingyi Xia, Li Li, Yunze Li, Manyan Hu, Tianrui Zhang, Qinghua Feng, Wenlei Li, Yuan Zhu, Minghua Wu
Summary: This study shows that fasting blood glucose (FBG) level is significantly associated with unfavorable outcome after acute ischemic stroke (AIS) in patients. The risk of unfavorable outcome increases significantly when FBG is above 5.5 mmol/L.
CLINICAL NEUROLOGY AND NEUROSURGERY
(2024)